## **Issue of Shares**

Arrow Minerals Limited (ASX: AMD) (**Arrow** or the **Company**) advises the issue of a total of 3,210,000,000 shares (**Shares**) as approved by shareholders at the Company's recent General Meeting, including:

- 3,050,000,000 Placement shares raising \$3,050,000, being the Tranche 2 Placement securities<sup>1</sup>;
- 80,000,000 Lead Manager shares; and
- 80,000,000 Corporate Adviser shares.

An Appendix 2A has been lodged together with this announcement.

## Notice Under Section 708A(5)(e) of the Corporations Act 2001

In respect of the Shares, Arrow gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) of the following:

- 1. The Shares were issued without disclosure under Part 6D.2 of the Act;
- 2. As at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) section 674 and 674A of the Act; and
- 3. As at the date of this notice, there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

Announcement authorised for release by the Managing Director of Arrow.

For further information visit <u>www.arrowminerals.com.au</u> or contact: info@arrowminerals.com.au

## **FOLLOW US**

**Twitter:** https://twitter.com/arrowminerals

LinkedIn: https://www.linkedin.com/company/arrow-minerals-limited

## **About Arrow Minerals**

Arrow Minerals is focused on creating value for shareholders through the discovery and development of multiple economic iron ore deposits at its Simandou North Iron Project in Guinea, West Africa. Arrow is rapidly advancing exploration and other evaluation work with a clear path to earn 100% (AMD ASX Announcement 30 August 2023) of the project. The company also aims to fully realise the value of the project by accessing multi-user rail infrastructure.

<sup>&</sup>lt;sup>1</sup> Refer ASX Announcement dated 13 December 2023.